AgingResearch.NewsJoin free

Vivolux

CompanySweden

Vivolux develops one asset, in phase 1 (VLX1570 in multiple myeloma). Mostly small molecule acting on apoptosis, proteostasis and USP14; based in Sweden.

1
Asset
Furthest stage
Phase 1
1
Trial
0
Signals

Pipeline

1

  • VLX1570

    Inhibits 19S proteasome deubiquitinases USP14 and UCHL5, inducing proteotoxic stress and apoptosis.

    Phase 1, Small molecule, Apoptosis, Proteostasis, multiple myeloma

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms5
  • Trials1
  • Similar companies6

Intelligence